Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Kidney Cancer-Pipeline Review, H1 2015

Kidney Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Kidney Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Kidney Cancer-Pipeline Review, H1 2015', provides an overview of the Kidney Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Kidney Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Kidney Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Kidney Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Kidney Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Kidney Cancer Overview 8

Therapeutics Development 9

Kidney Cancer-Therapeutics under Development by Companies 11

Kidney Cancer-Therapeutics under Investigation by Universities/Institutes 22

Kidney Cancer-Pipeline Products Glance 24

Kidney Cancer-Products under Development by Companies 28

Kidney Cancer-Products under Investigation by Universities/Institutes 41

Kidney Cancer-Companies Involved in Therapeutics Development 43

Kidney Cancer-Therapeutics Assessment 158

Drug Profiles 178

Kidney Cancer-Recent Pipeline Updates 561

Kidney Cancer-Dormant Projects 792

Kidney Cancer-Discontinued Products 810

Kidney Cancer-Product Development Milestones 814

Appendix 824

List of Tables

Number of Products under Development for Kidney Cancer, H1 2015 31

Number of Products under Development for Kidney Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 34

Number of Products under Development by Companies, H1 2015 (Contd..1) 35

Number of Products under Development by Companies, H1 2015 (Contd..2) 36

Number of Products under Development by Companies, H1 2015 (Contd..3) 37

Number of Products under Development by Companies, H1 2015 (Contd..4) 38

Number of Products under Development by Companies, H1 2015 (Contd..5) 39

Number of Products under Development by Companies, H1 2015 (Contd..6) 40

Number of Products under Development by Companies, H1 2015 (Contd..7) 41

Number of Products under Development by Companies, H1 2015 (Contd..8) 42

Number of Products under Development by Companies, H1 2015 (Contd..9) 43

Number of Products under Investigation by Universities/Institutes, H1 2015 45

Comparative Analysis by Late Stage Development, H1 2015 46

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Development, H1 2015 48

Comparative Analysis by Unknown Stage Development, H1 2015 49

Products under Development by Companies, H1 2015 50

Products under Development by Companies, H1 2015 (Contd..1) 51

Products under Development by Companies, H1 2015 (Contd..2) 52

Products under Development by Companies, H1 2015 (Contd..3) 53

Products under Development by Companies, H1 2015 (Contd..4) 54

Products under Development by Companies, H1 2015 (Contd..5) 55

Products under Development by Companies, H1 2015 (Contd..6) 56

Products under Development by Companies, H1 2015 (Contd..7) 57

Products under Development by Companies, H1 2015 (Contd..8) 58

Products under Development by Companies, H1 2015 (Contd..9) 59

Products under Development by Companies, H1 2015 (Contd..10) 60

Products under Development by Companies, H1 2015 (Contd..11) 61

Products under Development by Companies, H1 2015 (Contd..12) 62

Products under Investigation by Universities/Institutes, H1 2015 63

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 64

Kidney Cancer-Pipeline by Acceleron Pharma, Inc., H1 2015 65

Kidney Cancer-Pipeline by Advanced Cancer Therapeutics, H1 2015 66

Kidney Cancer-Pipeline by Advaxis, Inc., H1 2015 67

Kidney Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 68

Kidney Cancer-Pipeline by Alethia Biotherapeutics Inc., H1 2015 69

Kidney Cancer-Pipeline by Altor BioScience Corporation, H1 2015 70

Kidney Cancer-Pipeline by Ambrx, Inc., H1 2015 71

Kidney Cancer-Pipeline by Amgen Inc., H1 2015 72

Kidney Cancer-Pipeline by Amorfix Life Sciences Ltd., H1 2015 73

Kidney Cancer-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 74

Kidney Cancer-Pipeline by Angiogene Pharmaceuticals Limited, H1 2015 75

Kidney Cancer-Pipeline by APEIRON Biologics AG, H1 2015 76

Kidney Cancer-Pipeline by arGEN-X BV, H1 2015 77

Kidney Cancer-Pipeline by Argos Therapeutics, Inc., H1 2015 78

Kidney Cancer-Pipeline by ArQule, Inc., H1 2015 79

Kidney Cancer-Pipeline by Astellas Pharma Inc., H1 2015 80

Kidney Cancer-Pipeline by AstraZeneca Plc, H1 2015 81

Kidney Cancer-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 82

Kidney Cancer-Pipeline by Bayer AG, H1 2015 83

Kidney Cancer-Pipeline by Beta Pharma, Inc., H1 2015 84

Kidney Cancer-Pipeline by BIND Therapeutics, Inc., H1 2015 85

Kidney Cancer-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 86

Kidney Cancer-Pipeline by Biogenomics Limited, H1 2015 87

Kidney Cancer-Pipeline by Bionomics Limited, H1 2015 88

Kidney Cancer-Pipeline by BioNovion B.V., H1 2015 89

Kidney Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 90

Kidney Cancer-Pipeline by Boston Biomedical, Inc., H1 2015 91

Kidney Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 92

Kidney Cancer-Pipeline by Caladrius Biosciences, Inc. , H1 2015 93

Kidney Cancer-Pipeline by Calithera Biosciences, Inc., H1 2015 94

Kidney Cancer-Pipeline by CASI Pharmaceuticals Inc., H1 2015 95

Kidney Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 96

Kidney Cancer-Pipeline by Celltrion, Inc., H1 2015 97

Kidney Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 98

Kidney Cancer-Pipeline by Chipscreen Biosciences Ltd, H1 2015 99

Kidney Cancer-Pipeline by Conkwest, Inc., H1 2015 100

Kidney Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 101

Kidney Cancer-Pipeline by CureTech Ltd., H1 2015 102

Kidney Cancer-Pipeline by Cytune Pharma SAS, H1 2015 103

Kidney Cancer-Pipeline by Ecrins Therapeutics SAS, H1 2015 104

Kidney Cancer-Pipeline by Eisai Co., Ltd., H1 2015 105

Kidney Cancer-Pipeline by Eli Lilly and Company, H1 2015 106

Kidney Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 107

Kidney Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 108

Kidney Cancer-Pipeline by Exelixis, Inc., H1 2015 109

Kidney Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 110

Kidney Cancer-Pipeline by Genor BioPharma Co., Ltd., H1 2015 111

Kidney Cancer-Pipeline by GenSpera, Inc., H1 2015 112

Kidney Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 113

Kidney Cancer-Pipeline by Glycotope GmbH, H1 2015 114

Kidney Cancer-Pipeline by Hemispherx Biopharma, Inc., H1 2015 115

Kidney Cancer-Pipeline by Hospira, Inc., H1 2015 116

Kidney Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 117

Kidney Cancer-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 118

Kidney Cancer-Pipeline by immatics biotechnologies GmbH, H1 2015 119

Kidney Cancer-Pipeline by Immune Design Corp., H1 2015 120

Kidney Cancer-Pipeline by Immunicum AB, H1 2015 121

Kidney Cancer-Pipeline by ImmunoGen, Inc., H1 2015 122

Kidney Cancer-Pipeline by Immunomedics, Inc., H1 2015 123

Kidney Cancer-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 124

Kidney Cancer-Pipeline by Incyte Corporation, H1 2015 125

Kidney Cancer-Pipeline by Innate Immunotherapeutics Limited, H1 2015 126

Kidney Cancer-Pipeline by InteRNA Technologies B.V., H1 2015 127

Kidney Cancer-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 128

Kidney Cancer-Pipeline by Johnson & Johnson, H1 2015 129

Kidney Cancer-Pipeline by KAHR medical Ltd., H1 2015 130

Kidney Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 131

Kidney Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 132

Kidney Cancer-Pipeline by Mabion SA, H1 2015 133

Kidney Cancer-Pipeline by MacroGenics, Inc., H1 2015 134

Kidney Cancer-Pipeline by MediaPharma s.r.l., H1 2015 135

Kidney Cancer-Pipeline by MediGene AG, H1 2015 136

Kidney Cancer-Pipeline by MedImmune, LLC, H1 2015 137

Kidney Cancer-Pipeline by Merck & Co., Inc., H1 2015 138

Kidney Cancer-Pipeline by Merck KGaA, H1 2015 139

Kidney Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 140

Kidney Cancer-Pipeline by Mirati Therapeutics Inc., H1 2015 141

Kidney Cancer-Pipeline by Mologen AG, H1 2015 142

Kidney Cancer-Pipeline by NewLink Genetics Corporation, H1 2015 143

Kidney Cancer-Pipeline by Novartis AG, H1 2015 144

Kidney Cancer-Pipeline by Omeros Corporation, H1 2015 145

Kidney Cancer-Pipeline by Oncobiologics, Inc., H1 2015 146

Kidney Cancer-Pipeline by Oncolys BioPharma Inc., H1 2015 147

Kidney Cancer-Pipeline by OncoMax, H1 2015 148

Kidney Cancer-Pipeline by Oncothyreon Inc., H1 2015 149

Kidney Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 150

Kidney Cancer-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 151

Kidney Cancer-Pipeline by Panacea Biotec Limited, H1 2015 152

Kidney Cancer-Pipeline by Panacela Labs, Inc., H1 2015 153

Kidney Cancer-Pipeline by Peloton Therapeutics, Inc., H1 2015 154

Kidney Cancer-Pipeline by Pfizer Inc., H1 2015 155

Kidney Cancer-Pipeline by Pharmicell Co., Ltd., H1 2015 156

Kidney Cancer-Pipeline by Pivotal BioSciences, Inc., H1 2015 157

Kidney Cancer-Pipeline by Plexxikon Inc., H1 2015 158

Kidney Cancer-Pipeline by Pono Pharma, H1 2015 159

Kidney Cancer-Pipeline by Prima BioMed Ltd., H1 2015 160

Kidney Cancer-Pipeline by PsiOxus Therapeutics Limited, H1 2015 161

Kidney Cancer-Pipeline by Qu Biologics Inc., H1 2015 162

Kidney Cancer-Pipeline by Recombio S.L, H1 2015 163

Kidney Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 164

Kidney Cancer-Pipeline by Sanofi, H1 2015 165

Kidney Cancer-Pipeline by Seattle Genetics, Inc., H1 2015 166

Kidney Cancer-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 167

Kidney Cancer-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 168

Kidney Cancer-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 169

Kidney Cancer-Pipeline by TC BioPharm Limited, H1 2015 170

Kidney Cancer-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 171

Kidney Cancer-Pipeline by Theravectys S.A., H1 2015 172

Kidney Cancer-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 173

Kidney Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 174

Kidney Cancer-Pipeline by TVAX Biomedical, Inc., H1 2015 175

Kidney Cancer-Pipeline by Vascular Biogenics Ltd., H1 2015 176

Kidney Cancer-Pipeline by Vaxeal Holding SA, H1 2015 177

Kidney Cancer-Pipeline by Welichem Biotech Inc., H1 2015 178

Kidney Cancer-Pipeline by Zymeworks Inc., H1 2015 179

Assessment by Monotherapy Products, H1 2015 180

Assessment by Combination Products, H1 2015 181

Number of Products by Stage and Target, H1 2015 183

Number of Products by Stage and Mechanism of Action, H1 2015 191

Number of Products by Stage and Route of Administration, H1 2015 197

Number of Products by Stage and Molecule Type, H1 2015 199

Kidney Cancer Therapeutics-Recent Pipeline Updates, H1 2015 583

Kidney Cancer-Dormant Projects, H1 2015 814

Kidney Cancer-Dormant Projects (Contd..1), H1 2015 815

Kidney Cancer-Dormant Projects (Contd..2), H1 2015 816

Kidney Cancer-Dormant Projects (Contd..3), H1 2015 817

Kidney Cancer-Dormant Projects (Contd..4), H1 2015 818

Kidney Cancer-Dormant Projects (Contd..5), H1 2015 819

Kidney Cancer-Dormant Projects (Contd..6), H1 2015 820

Kidney Cancer-Dormant Projects (Contd..7), H1 2015 821

Kidney Cancer-Dormant Projects (Contd..8), H1 2015 822

Kidney Cancer-Dormant Projects (Contd..9), H1 2015 823

Kidney Cancer-Dormant Projects (Contd..10), H1 2015 824

Kidney Cancer-Dormant Projects (Contd..11), H1 2015 825

Kidney Cancer-Dormant Projects (Contd..12), H1 2015 826

Kidney Cancer-Dormant Projects (Contd..13), H1 2015 827

Kidney Cancer-Dormant Projects (Contd..14), H1 2015 828

Kidney Cancer-Dormant Projects (Contd..15), H1 2015 829

Kidney Cancer-Dormant Projects (Contd..16), H1 2015 830

Kidney Cancer-Dormant Projects (Contd..17), H1 2015 831

Kidney Cancer-Discontinued Products, H1 2015 832

Kidney Cancer-Discontinued Products (Contd..1), H1 2015 833

Kidney Cancer-Discontinued Products (Contd..2), H1 2015 834

Kidney Cancer-Discontinued Products (Contd..3), H1 2015 835

List of Figures

Number of Products under Development for Kidney Cancer, H1 2015 31

Number of Products under Development for Kidney Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Comparative Analysis by Clinical Stage Development, H1 2015 47

Comparative Analysis by Early Stage Products, H1 2015 48

Assessment by Monotherapy Products, H1 2015 180

Number of Products by Top 10 Targets, H1 2015 182

Number of Products by Stage and Top 10 Targets, H1 2015 182

Number of Products by Top 10 Mechanism of Actions, H1 2015 190

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 190

Number of Products by Top 10 Routes of Administration, H1 2015 196

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 196

Number of Products by Top 10 Molecule Types, H1 2015 198

Number of Products by Stage and Top 10 Molecule Types, H1 2015 198

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

Advanced Cancer Therapeutics

Advaxis, Inc.

Advenchen Laboratories, LLC

Alethia Biotherapeutics Inc.

Altor BioScience Corporation

Ambrx, Inc.

Amgen Inc.

Amorfix Life Sciences Ltd.

Ampio Pharmaceuticals, Inc.

Angiogene Pharmaceuticals Limited

APEIRON Biologics AG

arGEN-X BV

Argos Therapeutics, Inc.

ArQule, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Aurigene Discovery Technologies Limited

Bayer AG

Beta Pharma, Inc.

BIND Therapeutics, Inc.

Bio-Cancer Treatment International Limited

Biogenomics Limited

Bionomics Limited

BioNovion B.V.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Caladrius Biosciences, Inc.

Calithera Biosciences, Inc.

CASI Pharmaceuticals Inc.

Celldex Therapeutics, Inc.

Celltrion, Inc.

Cerulean Pharma, Inc.

Chipscreen Biosciences Ltd

Conkwest, Inc.

Corcept Therapeutics Incorporated

CureTech Ltd.

Cytune Pharma SAS

Ecrins Therapeutics SAS

Eisai Co., Ltd.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Esperance Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Genor BioPharma Co., Ltd.

GenSpera, Inc.

GlaxoSmithKline Plc

Glycotope GmbH

Hemispherx Biopharma, Inc.

Hospira, Inc.

Hutchison MediPharma Limited

Ildong Pharmaceutical Co., Ltd.

immatics biotechnologies GmbH

Immune Design Corp.

Immunicum AB

ImmunoGen, Inc.

Immunomedics, Inc.

Inbiopro Solutions Pvt. Ltd.

Incyte Corporation

Innate Immunotherapeutics Limited

InteRNA Technologies B.V.

Jiangsu Hengrui Medicine Co., Ltd.

Johnson & Johnson

KAHR medical Ltd.

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Mabion SA

MacroGenics, Inc.

MediaPharma s.r.l.

MediGene AG

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

Mologen AG

NewLink Genetics Corporation

Novartis AG

Omeros Corporation

Oncobiologics, Inc.

Oncolys BioPharma Inc.

OncoMax

Oncothyreon Inc.

Ono Pharmaceutical Co., Ltd.

Onyx Pharmaceuticals, Inc.

Panacea Biotec Limited

Panacela Labs, Inc.

Peloton Therapeutics, Inc.

Pfizer Inc.

Pharmicell Co., Ltd.

Pivotal BioSciences, Inc.

Plexxikon Inc.

Pono Pharma

Prima BioMed Ltd.

PsiOxus Therapeutics Limited

Qu Biologics Inc.

Recombio S.L

Rexahn Pharmaceuticals, Inc.

Sanofi

Seattle Genetics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Syndax Pharmaceuticals, Inc.

Taiwan Liposome Company, Ltd.

TC BioPharm Limited

Teva Pharmaceutical Industries Limited

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

TVAX Biomedical, Inc.

Vascular Biogenics Ltd.

Vaxeal Holding SA

Welichem Biotech Inc.

Zymeworks Inc.

Kidney Cancer Therapeutic Products under Development, Key Players in Kidney Cancer Therapeutics, Kidney Cancer Pipeline Overview, Kidney Cancer Pipeline, Kidney Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com